SLN.L Share News (SLN)

SLN.L Information

There is currently no data for SLN

UK shareholder meetings calendar - next 7 days

Mon, 25th Oct 2021 16:03

Tuesday 26 October
Dispersion Holdings PLC	GM re share allotment
Wednesday 27 October
Cap-XX Ltd	AGM
Frontier Developments PLC	AGM
Hargreaves Services PLC	AGM
Ideagen PLC	AGM
Investment Co PLC	AGM
Invinity Energy Systems PLC	AGM
JPMorgan Global Growth & Income PLC	AGM
Mirada PLC	AGM
Pantheon International PLC	AGM
Puma VCT 11 PLC	GM re winding up
Springfield Properties PLC	AGM
Thursday 28 October
Brooks Macdonald Group PLC	AGM
City of London Investment Trust PLC	AGM
Filtronic PLC	AGM
Highbridge Tactical Credit Fund Ltd	AGM
JD Sports Fashion PLC	GM re proposed share sub-division
National Milk Records PLC	AGM
South32 Ltd	AGM
Tirupati Graphite PLC	AGM
Tirupati Graphite PLC	GM re acquisition, warrants
Friday 29 October
ADM Energy PLC	AGM
Adriatic Metals PLC	GM re funding package for Vares silver project
ITM Power PLC	AGM
Mattioli Woods PLC	AGM
MaxCyte PLC	AGM
OPG Power Ventures PLC	AGM
Sensyne Health PLC	AGM
Monday 1 November
Capital & Regional PLC	GM re capital raising
Electra Private Equity PLC	GM re Hostmore demerger
French Connection Group PLC	GM re takeover by MIP Holdings
Silence Therapeutics PLC	GM re cancellation of admission to trading
Vietnam Holding Ltd	AGM

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News

5 Mar 2013 12:33

STOCKS NEWS EUROPE-UK small caps firm 0.3 pct in midday trade

UK small caps advances 0.3 percent in midday trade, underperforming a 1 percent rise from the mid-caps, and a 0.9 percent gain from the blue chips. Silence Therapeutics jumps 23.5 percent, bouncing back from sharp losses in the previous session, after issuing a business update. The bi

5 Mar 2013 10:11

Silence Therapeutics gets German approval for cancer drug trial

March 5 (Reuters) - Biotech research and development company Silence Therapeutics said it received approval from German authorities for trials of its pancreatic cancer drug and was reviewing financing options for an aggressive expansion. Shares in the company rose as much as 20 percent on t

2 Jan 2013 12:28

Silence Therapeutics appoints Chief Medical Officer, shares rise

Silence Therapeutics has unveiled Michael Khan as the company's new Chief Medical Officer. He will oversee the phase II study on ATU027 for cancer and aid in the expansion of the private biotechnology company's clinical pipelines in oncology and acute lung injury. Khan is a consultant endocrinolog

2 Jan 2013 11:48

STOCKS NEWS EUROPE-UK small caps jump 1.1 pct around midday

The FTSE Small Caps index jumps 1.1 percent by midday on the first session of 2013, but still underperforms bigger gains by the FTSE 100 and FTSE 250 indexes, up 2.2 percent and 1.9 percent respectively. Silence Therapeutics adds 12.2 percent as the biotech firm appoints Michael Khan as its Chief M

29 Nov 2012 13:11

Silence Therapeutics raises five million pounds

Biotechnology firm Silence Therapeutics announced a five million pound placing to Henderson Global Investors and Ora Capital. New shares were placed at 2.5p representing a discount of around 19% to the market price. Funds raised will be used to expand the group's research activities in short in

28 Nov 2012 16:45

Mitchells & Butlers Chief buys 45,800 shares

Alistair Darby, the Chief Executive Officer of Mitchells & Butlers, the UK's largest operator of managed restaurants and pub, has boosted his holding in the group with the purchase of 45,800 shares. Darby, who only took up his current role in October, purchased the shares in two tranches; 44,716 on

19 Nov 2012 13:18

Silence Therapeutics granted two US patents

Shares in biotechnology firm Silence Therapeutics took a hit on Monday despite the company revealing that the US Patent and Trademark Office (USPTO) has granted its two new patents. The patents, which are for both its interfering RNA molecules and lipid complexes used in drug delivery, will extend

31 Jul 2012 11:51

Small caps: IndigoVision, Silence Therapeutics, Air Partner...

Air Partner, a provider of air charter services, has said underlying profit before tax for the year is expected to meet its forecasts. The firm's cost reduction programme is also now nearly complete and will realise 'significant cost savings' in the next financial year, with a one off restructuring

12 Jul 2012 10:52

Silence eschews underwriters in discounted share issue

Biotechnology firm Silence Therapeutics is to tap the market, offering shares at a sharp discount, as it seeks to bolster its balance sheet. The group plans to raise up to £5.7m before expenses through the issue of 940m new shares at a halfpenny each and a £1m convertible loan note issue. Of the n

27 Sep 2011 09:16

Silence Therapeutics lands new partnership

The biotech firm Silence Therapeutics has announced a partnership with what it describes as "one of the world's leading pharmaceutical companies". The agreement will see Silence work with the unnamed firm to see whether its "DACC" system for delivering compounds into target cells can be combined wi

27 Apr 2011 15:53

Silence losses grow despite higher revenues

Partnerships with big drug companies such as AstraZeneca lifted revenues at drug discovery group Silence Therapeutics in 2010, though losses also grew as it upped spending on development activities. Pre-tax losses came in at £8.8m, compared with £7.5m the previous year, on revenues that were up to

21 Mar 2011 17:42

Silence boosted by partner's test results

Silence Therapeutics recovered sharply from a 52-week low after it announced a favourable set of results from a phase II trial of a drug developed by Quark Pharmaceuticals. The Quark drug uses Silence's AtuRNAi technology. The treatment, which is intended to be used on patients with swollen retinas

7 Feb 2011 15:20

Silence ends bid talks

Shares in Silence Therapeutics have fallen by 15% after it admitted that bid talks had ended. AIM-quoted Silence originally said that it was in bid talks on 6 September 2010. The share price is not much higher than before the bid rumours started. Silence says that it received a number of indicat

21 Dec 2010 09:59

Small caps round-up: Forte Energy, Discovery Metals Proximagen...

Uranium company Forte Energy has been testing for rare earth elements (REE) in Guinea and the latest assay results indicate "provide a higher level of encouragement that a substantial body of REE mineralisation may exist within the company's 100% owned Firawa uranium project." "REE assays from thes

10 Nov 2010 14:38

Positive study for Silence

AIM-quoted Silence Therapeutics says that research shows that its lead RNA interference (RNAi) drug candidate, Atu027, prevents the spread of breast cancer to lungs. The findings were published in the latest edition of the scientific journal Clinical Cancer Research in a peer-reviewed paper entitl

Latest Share Chat

SLN.L Share News (SLN)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK shareholder meetings calendar - next 7 days

Login to your account

Quickpicks are a member only feature

Login to your account